저분자 CDMO 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Small Molecule CDMO Market size is expected to reach USD 157.80 Billion in 2034 from USD 82.58 Billion (2025) growing at a CAGR of 7.46% during 2026-2034.

The global small molecule CDMO market is experiencing strong growth as pharmaceutical companies continue to outsource drug development and manufacturing. Small molecule drugs remain widely used due to their stability, oral availability, and cost-effectiveness. Increasing drug pipelines and patent expirations are encouraging partnerships with CDMOs for efficient production.

Major drivers include rising demand for generic drugs and advancements in process optimization technologies. Expanding research in oncology and chronic disease therapies also supports growth. CDMOs offer scalability, regulatory expertise, and cost advantages, making them essential partners for pharmaceutical companies.

Future prospects are promising with increased adoption of continuous manufacturing and advanced analytical technologies. Expansion into emerging markets and growing clinical trial activity are expected to further boost demand for specialized small molecule manufacturing services.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Active Pharmaceutical Ingredients (API)
• Finished Drug Products

By Drug Type

• Innovators
• Generics

By Application

• Oncology
• Cardiovascular Disease
• Central Nervous System (CNS) Conditions
• Autoimmune/Inflammation
• Others

COMPANIES PROFILED

• Lonza, Catalent Inc, Thermo Fisher Scientific Inc, Cambrex Corporation, Bellen Chemistry, Siegfried Holding AG, Recipharm AB, Eurofins Scientific, Aurigene Pharmaceutical Services Ltd, CordenPharma International
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SMALL MOLECULE CDMO MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Active Pharmaceutical Ingredients (API) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Finished Drug Products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SMALL MOLECULE CDMO MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Type
• 5.2. Innovators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Generics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SMALL MOLECULE CDMO MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Central Nervous System (CNS) Conditions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Autoimmune/Inflammation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SMALL MOLECULE CDMO MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Drug Type
  • 7.2.3 By Application
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Drug Type
  • 7.3.3 By Application
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Drug Type
  • 7.4.3 By Application
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Drug Type
  • 7.5.3 By Application
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Drug Type
  • 7.6.3 By Application
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SMALL MOLECULE CDMO INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Lonza
  • 9.2.2 Catalent Inc
  • 9.2.3 Thermo Fisher Scientific Inc
  • 9.2.4 Cambrex Corporation
  • 9.2.5 Bellen Chemistry
  • 9.2.6 Siegfried Holding AG
  • 9.2.7 Recipharm AB
  • 9.2.8 Eurofins Scientific
  • 9.2.9 Aurigene Pharmaceutical Services Ltd
  • 9.2.10 CordenPharma International